Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

R6/1 brain hemisphere time series gene expression

ABSTRACT: HD R6/1 transgenic mouse line brain hemispheres dissected. RNA targets were created for transgenics and wildtypes at time points 18, 22 and 27 weeks. Profiles and data analysis performed using the Bioconductor software and linear model contrasts using LIMMA on RMA probeset summarys. Keywords: timecourse

ORGANISM(S): Mus musculus

PROVIDER: GSE3621 | GEO | 2007/07/31

SECONDARY ACCESSION(S): PRJNA93723

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of HD R6/1 transgenic mouse line brain hemispheres, time series

Project description:HD R6/1 transgenic mouse line brain hemispheres dissected. RNA targets were created for transgenics and wildtypes at time points 18, 22 and 27 weeks. Profiles and data analysis performed using the Bioconductor software and linear model contrasts using LIMMA on RMA probeset summarys. Experiment Overall Design: 18 samples extracted, 3 transgenic plus 3 littermate controls analysed at each timepoint.

2009-04-23 | E-GEOD-3621 | biostudies-arrayexpress

Triple treatment R6/2 mice

Project description:Huntington’s disease is a genetic disease caused by a single mutation. It is characterised by progressive movement, emotional and cognitive deficits. R6/2 transgenic mice carrying the Huntington’s disease mutation have a progressive neurological phenotype, including deterioration in cognitive function. The mechanism underlying the cognitive deficits in R6/2 mice is unknown, but dysregulated gene expression, reduced neurotransmitter levels and abnormal synaptic function are present before the cognitive decline becomes pronounced. Our goal here was to ameliorate the cognitive phenotype in R6/2 mice using a combination drug therapy (tacrine, moclobemide and creatine) aimed boosting neurotransmitter levels in the brain. Treatment from 5 weeks of age prevented deterioration in two different cognitive tasks until at least 12 weeks. However, motor deterioration continued unabated. Microarray analysis of global gene expression revealed that many genes significantly up- or down-regulated in untreated R6/2 mice had returned towards normal levels after treatment. Thus dysregulated gene expression was reversed by the combination treatment in the R6/2 mice and probably underlies the observed improvements in cognitive function. Our study shows that cognitive decline caused by a genetic mutation can be slowed by a combination drug treatment, and gives hope that cognitive symptoms in HD can be treated. Keywords = HD Keywords = Huntingtin Keywords = cognitive disorder Keywords = R6/2 Keywords = transgenic mice Keywords = gene expression Keywords = microarray Keywords: ordered

2004-06-01 | GSE857 | GEO

S. pneumoniae R6 LVX

Project description:An exponentially growing culture of strain R6 in AGCH at OD620nm=0.4 was either non-treated or treated with two LVX concentrations: 0.125 ug/ml LVX (0.5x MIC of R6) and 2.5 ug/ml LVX (10x MIC of R6). Samples were taken before treatment (0 min), at 15, 30 and 60 min in the non-treated culture, and at 5, 15 ,30 and 60 min in the LVX treated cultures

2014-01-29 | E-MEXP-3809 | biostudies-arrayexpress

Streptococcus pneumoniae R6

Project description:Streptococcus pneumoniae R6 genomic DNA

| PRJNA251531 | ENA

Acetivibrio thermocellus strain:R6

Project description:Hungateiclostridium thermocellum R6 Resequencing

| PRJNA499310 | ENA

Thalassolituus oleivorans R6-15

Project description:Thalassolituus oleivorans R6-15 Genome Sequencing

| PRJNA170393 | ENA

Streptomyces rimosus R6-500

Project description:Streptomyces rimosus R6-500 Genome sequencing

| PRJNA227408 | ENA

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed R6/2 mice.

Project description:R6/2 and WT mice treated orally twice a day with vehicle (10% HPβCD), and R6/2 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 - 12 weeks of age.

2017-09-23 | GSE104086 | GEO

Six-week-old R6/2 HD mouse striatum

Project description:Wild-type CBAxC57BL/6 (6 weeks of age) and HD Exon 1 R6/2 CBAxC57BL/6 (6 weeks of age). Control groups for two drug studies. All animals injected with normal saline 30-60 minutes prior to sacrifice. Keywords: parallel sample

2011-10-13 | GSE1980 | GEO

MicroRNA expression in R6/2 and wild-type mouse brain

Project description:We investigated miRNA expression profiles in R6/2 and wild-type mice. The results suggested that there was a difference in the expression of miRNAs between the mice.

2018-04-11 | GSE100792 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data